{"id":"W4310798566","doi":"10.1016/j.esmoop.2022.100634","title":"Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Hospital Foundation","funders":"Ministero della Salute; Amgen; Prostate Cancer Foundation","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Internal medicine; Overall survival; Oncology; Progression-free survival; Expanded access; Response Evaluation Criteria in Solid Tumors; Urology; Cancer; Progressive disease; Disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005269823,0.0001638079,0.0003088483,0.0001106631,0.0001522313,0.00007793682,0.0005217305,0.0000212204,0.00007954203],"category_scores_gemma":[0.00004043072,0.00009212334,0.00004148114,0.000584678,0.0000652301,0.0002084513,0.0005007114,0.0002109362,5.719596e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001993209,"about_ca_system_score_gemma":0.0001257173,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00277136,"about_ca_topic_score_gemma":0.001873438,"domain_scores_codex":[0.998273,0.0003529724,0.0003391736,0.0003098879,0.0005148032,0.0002101893],"domain_scores_gemma":[0.999123,0.00009943495,0.0002028099,0.0004765771,0.00005465012,0.00004355771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000857491,0.001113453,0.9924452,0.00009769688,0.00002809276,0.00004628964,0.002620971,0.0002286315,0.00002547161,0.000007455213,0.0001289311,0.002400276],"study_design_scores_gemma":[0.007891296,0.001813322,0.9845666,0.0001159964,0.0001191398,0.0000152205,0.000666767,0.0001128181,0.004447145,0.00006145696,0.0000852159,0.0001050161],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940019,0.00005564894,0.000001241672,0.0005528655,0.00003891416,0.00399788,0.00001480989,0.000007083571,0.001329686],"genre_scores_gemma":[0.9988095,0.000002930882,0.0002092139,0.00009301448,0.000008729562,0.0006239466,0.00009491869,0.00002218213,0.0001355994],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007878634,"threshold_uncertainty_score":0.4189486,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0410528661734179,"score_gpt":0.2901908751238391,"score_spread":0.2491380089504212,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}